LGD-4033 Cas No.1165910-22-4
- CasNo：1165910-22-4
- Molecular Formula：C14H12F6N2O
- Purity：
- Molecular Weight：
Product Details
|
1165910-22-4 Name |
|
|
Name |
LGD-4033 |
|
Synonym |
4-((R)-2-((R)-2,2,2-trifluoro-1-hydroxyethyl)pyrrolidin-1-yl)-2-trifluoroMethyl)benzonitrile(LGD-4033);LGD-4033;4-[(2R)-2-[(1R)-2,2,2-Trifluoro-1-hydroxyethyl]-1-pyrrolidinyl]-2-(trifluoromethyl)benzonitrile;4-((R)-2-((R)-2,2,2-Trifluoro-1-hydroxyethyl)pyrrolidin-1-yl)-2-trifluoroMethyl)benzonitrile;LIGANDROL;4-[(2R)-2-[(1R)-2,2,2-trifluoro-1-hydroxyethyl]pyrrolidin-1-yl]-2-(trifluoromethyl)benzonitrile;lgd 4033 sarms powder lgd-4033 ligandrol;POWDER LGD-4033 LIGANDROL;LGD-4033 |
|
1165910-22-4 Biological Activity |
|
|
Description |
LGD-4033 is a novel nonsteroidal, oral SARM that binds to androgen receptor with high affinity (Ki of 1 nM) and selectivity.IC50 value: 1 nM (Ki, for androgen receptor) Target: androgen receptorin vitro: LGD-4033, a novel nonsteroidal oral, selective androgen receptor modulator, binds androgen receptor with high affinity and selectivity.in vivo: LGD-4033 has demonstrated anabolic activity in the muscle, anti-resorptive and anabolic activity in bone, and robust selectivity for muscle versus prostate In animal models. LGD-4033 is well tolerated, has a long elimination half-life and dose-proportional accumulation upon multiple dosing. LGD-4033 is safe, has favorable pharmacokinetic profile, and increases lean body mass even during this short period without change in prostate-specific antigen. |
|
Related Catalog |
Signaling Pathways >> Others >> Androgen Receptor Research Areas >> Endocrinology |
|
References |
[1]. Basaria S,et al. The safety, pharmacokinetics, and effects of LGD-4033, a novel nonsteroidal oral, selective androgen receptor modulator, in healthy young men. J Gerontol A Biol Sci Med Sci. 2013 Jan;68(1):87-95. |
|
1165910-22-4 Chemical & Physical Properties |
|
|
Melting point |
108 - 111°C |
|
Boiling point |
439.9±45.0 °C at 760 mmHg |
|
Density |
1.5±0.1 g/cm3 |
|
Molecular Formula |
C14H12F6N2O |
|
Molecular Weight |
338.248 |
|
Flash Point |
219.8±28.7 °C |
|
PSA |
47.26000 |
|
LogP |
4.04 |
|
Exact Mass |
338.085388 |
|
Vapour Pressure |
0.0±1.1 mmHg at 25°C |
|
Index of Refraction |
1.496 |
|
1165910-22-4 Description |
|
LGD-4033 is a Selective Androgen Receptor Modulator (SARM). SARMs are a class of non-steroidal anabolic agents that bind androgen receptors with high affinity. LGD-4033 has been shown to provide benefits similar to traditional anabolic agents, (e.g., increased muscle mass, fat loss, and improved bone density) but with far fewer side effects (e.g., oily skin, acne, over-conversion to estrogen, etc.). Both men and women may also appreciate improved libido. All of these benefits are achieved without increasing androgen levels. Its anabolic effects are roughly the same or greater than testosterone, even at low doses. Some prescribers will recommend a trial of SARMs for low testosterone levels prior to utilizing testosterone replacement therapy. |
|
1165910-22-4 Uses |
|
LGD-4033 is a nonsteroidal oral, selective androgen receptor modulator, in healthy young men. |
